Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
46. |
ECCT/23/06/02 | IMAGINE-TBM A Phase II, Randomized, Open-Label Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents with Tuberculous Meningitis: Improved Management with Antimicrobial AGents Isoniazid rifampiciN LinEzolid for TBM (IMAGINE-TBM). |
Principal Investigator(s) 1. Deborah Chepng\'eno Langat Site(s) in Kenya KEMRI/WRP CRC |
View |
47. |
ECCT/25/05/13 | IVI CCV 002 A Phase II, randomized, controlled, age-descending study in adults and children to evaluate the safety and immunogenicity of the OSP:rTTHc Cholera Conjugate Vaccine in cholera-endemic region |
Principal Investigator(s) 1. Walter Jaoko Site(s) in Kenya KAVI - Institute of Clinical Research, University of Nairobi |
View |
48. |
ECCT/20/05/01 | ChAdOx1 nCoV-19 trial A phase Ib/II single-blinded, randomised, controlled study to determine safety, immunogenicity and efficacy of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19 in adults in Kenya |
Principal Investigator(s) 1. George Warimwe Site(s) in Kenya KEMRI-CGMRC |
View |
49. |
ECCT/11/10/05 | A Phase 3, Open Label, Randomized, Comparative Study to Evaluate Azithromycin Plus Chloroquine and Sulfadoxine Plus Pyrimethamine Combinations for Intermittent Preventive Treatment of Falciparum Malaria Infection in Pregnant Women in Africa. WRAIR #1775, KEMRI SSC #1983 |
Principal Investigator(s) 1. Lucas Otieno Tina Site(s) in Kenya 1. KEMRI/WRP Kombewa (Kisumu county) |
View |
50. |
ECCT/16/02/06 | A study of the safety and immune response of 2 doses of a new Shigella vaccine in Kenyan adults. A Phase 2a, observer blind, randomized, controlled, Single Center Study to evaluate the Safety, Reactogenicity and Immunogenicity of 2 doses of the GVGH 1790GAHB Vaccine against Shigella sonnei, administered intramuscularly in Adult Subjects from a country endemic for shigellosis [GVGH study H03_04TP] |
Principal Investigator(s) 1. Christina Wesonga Obiero Site(s) in Kenya Kenya Medical Research Institute (KEMRI) -Wellcome Trust Research Programme |
View |